Genmab A/S (OTCMKTS:GNMSF) sets new 12-month low at $270.55


Shares of Genmab A/S (OTCMKTS: GNMSFGet a rating) hit a new 52-week low during Monday’s trading. The company traded as low as $270.55 and last traded at $270.55, with volume trading at 1231 shares. The stock had previously closed at $287.33.

The stock has a 50-day moving average of $328.01 and a 200-day moving average of $346.72. The stock has a market capitalization of $17.69 billion, a price-earnings ratio of 48.23 and a beta of 0.89.

Genmab A/S (OTCMKTS: GNMSFGet a rating) last reported quarterly earnings data on Wednesday, May 11. The company reported EPS of $1.06 for the quarter. The company had revenue of $319.54 million in the quarter. Genmab A/S achieved a return on equity of 10.90% and a net margin of 26.34%.

Genmab A/S Company Profile (OTCMKTS: GNMSF)

Genmab A/S develops therapeutic antibodies for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Read more



Get news and reviews for Genmab A/S Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Genmab A/S and related companies with MarketBeat.com’s free daily email newsletter.

Comments are closed.